DK3230316T3 - Behandling af aldersrelateret makuladegeneration med en lille aktiv choroidal neovaskularisationslæsion - Google Patents

Behandling af aldersrelateret makuladegeneration med en lille aktiv choroidal neovaskularisationslæsion Download PDF

Info

Publication number
DK3230316T3
DK3230316T3 DK15819965.3T DK15819965T DK3230316T3 DK 3230316 T3 DK3230316 T3 DK 3230316T3 DK 15819965 T DK15819965 T DK 15819965T DK 3230316 T3 DK3230316 T3 DK 3230316T3
Authority
DK
Denmark
Prior art keywords
maculade
deneration
lession
age
treatment
Prior art date
Application number
DK15819965.3T
Other languages
English (en)
Inventor
Oliver Zeitz
Olaf Sowade
Haiyan Wu
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55069121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3230316(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2014/093548 external-priority patent/WO2016090590A1/en
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of DK3230316T3 publication Critical patent/DK3230316T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DK15819965.3T 2014-12-11 2015-12-10 Behandling af aldersrelateret makuladegeneration med en lille aktiv choroidal neovaskularisationslæsion DK3230316T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/093548 WO2016090590A1 (en) 2014-12-11 2014-12-11 Treatment of age related macular degeneration with a small active choroidalneovascularizationlesion
CN2015089251 2015-09-09
PCT/US2015/065022 WO2016094673A1 (en) 2014-12-11 2015-12-10 Treatment of age related macular degeneration with a small active choroidal neovascularization lesion

Publications (1)

Publication Number Publication Date
DK3230316T3 true DK3230316T3 (da) 2022-03-28

Family

ID=55069121

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15819965.3T DK3230316T3 (da) 2014-12-11 2015-12-10 Behandling af aldersrelateret makuladegeneration med en lille aktiv choroidal neovaskularisationslæsion

Country Status (16)

Country Link
US (2) US20170326106A1 (da)
EP (2) EP3230316B1 (da)
JP (3) JP7320919B2 (da)
CN (3) CN106999511A (da)
AU (3) AU2015360496B2 (da)
CA (1) CA2970315C (da)
DK (1) DK3230316T3 (da)
ES (1) ES2907148T3 (da)
HR (1) HRP20220066T1 (da)
HU (1) HUE057653T2 (da)
LT (1) LT3230316T (da)
PL (1) PL3230316T3 (da)
PT (1) PT3230316T (da)
RS (1) RS62827B1 (da)
SI (1) SI3230316T1 (da)
WO (1) WO2016094673A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973142B2 (en) 2006-04-07 2011-07-05 Warner Chilcott Company Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3230316B1 (en) 2014-12-11 2022-01-05 Bayer HealthCare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
US10525035B2 (en) * 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3626503B2 (ja) 1996-10-25 2005-03-09 ギリード・サイエンシズ・インコーポレーテッド 血管内皮増殖因子（ｖｅｇｆ）核酸リガンド複合体
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
MEP3208A (xx) 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
AU2002236988A1 (en) * 2001-02-06 2002-08-19 Novartis Ag Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
KR20140043313A (ko) * 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP3230316B1 (en) 2014-12-11 2022-01-05 Bayer HealthCare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion

Also Published As

Publication number Publication date
JP7320919B2 (ja) 2023-08-04
CN112826934A (zh) 2021-05-25
EP3985023A1 (en) 2022-04-20
EP3230316B1 (en) 2022-01-05
CN114306575A (zh) 2022-04-12
PL3230316T3 (pl) 2022-05-02
JP2021004262A (ja) 2021-01-14
ES2907148T3 (es) 2022-04-22
JP2022183183A (ja) 2022-12-08
AU2021107575A4 (en) 2022-01-06
HRP20220066T1 (hr) 2022-04-15
HUE057653T2 (hu) 2022-05-28
WO2016094673A1 (en) 2016-06-16
AU2015360496B2 (en) 2021-09-30
SI3230316T1 (sl) 2022-05-31
US20170326106A1 (en) 2017-11-16
JP2017537117A (ja) 2017-12-14
CA2970315C (en) 2023-08-22
PT3230316T (pt) 2022-02-24
LT3230316T (lt) 2022-02-10
RS62827B1 (sr) 2022-02-28
CN106999511A (zh) 2017-08-01
CA2970315A1 (en) 2016-06-16
EP3230316A1 (en) 2017-10-18
US20190381008A1 (en) 2019-12-19
AU2015360496A1 (en) 2017-05-25
AU2021245214A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
DK3230316T3 (da) Behandling af aldersrelateret makuladegeneration med en lille aktiv choroidal neovaskularisationslæsion
DK3191502T3 (da) Målrettet indgivelse af tertiært aminholdige lægemiddelstoffer
DK3134530T3 (da) Behandling af hyperbilirubinæmi
BR112018009951A2 (pt) fármaco oftálmico
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3171928T3 (da) Stimulationsmønstre til behandling af tørt øje
DK3347457T3 (da) MACS-baseret oprensning af stamcelleafledt retinalt pigmentepitel
BR112016030368A2 (pt) composição oftálmica
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3154561T3 (da) Modulering af komplementaktivitet
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
BR112017007281A2 (pt) composição ativa de amaciante de tecidos
DK3685847T3 (da) Modulatorer af komplementaktivitet
DK3139855T3 (da) Scanning af tandløse patienter
DK3307267T3 (da) Behandling af multipel sklerose
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme